PRUNUS Therapeutics

Immuno-oncology

PRUNUS Therapeutics discovers and develops innovative therapeutics for human and animal healthcare. PRUNUS’ main platform focuses on an innovative cancer therapy that harnesses the power of self–immune system to find and reject cancer cells.

Approach

Targeted Neoantigen Loading – Selectively loading a foreign immugenic molecule into cancer cells. The approach takes advantage of puromycin-based prodrug technology to selectively mark a broad spectrum of cancer cells with a small tag (neoantigen). The neoantigen triggers the immune system to recognize and reject them as “red-flagged invaders” like bacteria or viruses.

Publications

Nature Communications

Selective cancer targeting with prodrugs activated by histone deacetylases and a tumour-associated protease

Theranostics

Synthesis and Preclinical Evaluation of a Highly Improved Anticancer Prodrug Activated by Histone Deacetylases and Cathepsin L

Patents

Prodrugs for Selective Anticancer Therapy

Cancer Cell Specific Image Probes and Methods of Use

Development Stage

Proof-of-Concept / Pre-Clinical Development

Innovation Opportunity

  • Small Molecules
  • Biologics
  • Vaccines

Partnering

Interested in learning more? Submit your contact information below.